The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion to recommend approval of the combination of avelumab and axitinib for the frontline treatment of adult patients with advanced renal cell carcinoma.
Toni Choueiri, MD, discusses the rationale behind the Kidney Cancer Research Summit and recent advances in the renal cell carcinoma landscape.
The FDA has granted a priority review designation to a biologics license application for enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer who have received prior treatment with a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced, or metastatic setting.
Results from the second prespecified analysis of the TIVO-3 trial showed a hazard ratio for overall survival of 0.99 for tivozanib compared with sorafenib in patients with highly refractory metastatic renal cell carcinoma.
Petros Grivas, MD, highlights the evolving role of immunotherapy in bladder cancer and ongoing research slated to further progress along.
The European Commission has approved the combination of pembrolizumab (Keytruda) and axitinib (Inlyta) for the frontline treatment of patients with advanced renal cell carcinoma.
The combination of the off-the-shelf cancer immune primer ilixadencel and sunitinib elicited a 11% complete response rate in patients with metastatic renal cell carcinoma, according to topline findings from the phase II MERECA trial (NCT02432846).
Parminder Singh, MD, discusses ongoing research in advanced urothelial cancer and the focus on incorporating precision medicine in the field.
David D. Thiel, MD, provides perspective on the CARMENA findings in metastatic renal cell carcinoma.
Emerging immunotherapy combinations have offered a strong challenge to sunitinib (Sutent) in the setting of frontline advanced clear cell renal cell carcinoma.